Versican Plus Pi/L4R

Country: European Union

Language: Croatian

Source: EMA (European Medicines Agency)

Buy It Now

Active ingredient:

canine parainfluenza virus, leptospira and rabies virus.

Available from:

Zoetis Belgium S.A.

ATC code:

QI07AJ

INN (International Name):

canine parainfluenza virus, leptospira and rabies virus

Therapeutic group:

psi

Therapeutic area:

Imunomodulatori za псовые, živo i inaktivirano virusnih i bakterijskih cjepiva

Therapeutic indications:

Aktivna imunizacija pasa od шестинедельного dobi do spriječiti kliničkih simptoma i smanjenje zaraze izlučivanje uzrok pas парагриппа virus, kako bi se spriječilo klinički znakovi infekcije mokraćnog izlučivanje razlog Лептоспир сероваров Bratislava, тянитолкая, grippotyphosa i icterohaemorrhagiae i spriječiti smrtnost, klinički znakovi i uzroci infekcije na virus bjesnoće.

Product summary:

Revision: 5

Authorization status:

odobren

Authorization date:

2014-07-30

Patient Information leaflet

                                17
B. UPUTA O VMP
18
UPUTA O VMP:
VERSICAN PLUS PI/L4R LIOFILIZAT I SUSPENZIJA ZA SUSPENZIJU ZA
INJEKCIJU ZA PSE
1.
NAZIV I ADRESA NOSITELJA ODOBRENJA ZA STAVLJANJE U PROMET I
NOSITELJA ODOBRENJA ZA PROIZVODNJU ODGOVORNOG ZA PUŠTANJE
SERIJE U PROMET, AKO JE RAZLIČITO
Nositelj odobrenja za stavljanje u promet:
Zoetis Belgium SA
Rue Laid Burniat 1
1348 Louvain-la-Neuve
BELGIJA
Nositelj odobrenja za proizvodnju
odgovoran za puštanje serije u promet:
Bioveta, a.s.,
Komenského 212,
683 23 Ivanovice na Hané,
ČEŠKA REPUBLIKA
2.
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA
Versican Plus Pi/L4R liofilizat i suspenzija za suspenziju za
injekciju za pse
3.
KVALITATIVNI I KVANTITATIVNI SASTAV DJELATNE(IH) TVARI I DRUGIH
SASTOJAKA
Svaka doza od 1 ml sadržava:
DJELATNE TVARI:
LIOFILIZAT (ŽIVI ATENUIRANI):
MINIMALNO
MAKSIMALNO
Pseći parainfluenca virus tip 2, soj CPiV-2-Bio 15
10
3,1
TCID
50
*
10
5,1
TCID
50
SUSPENZIJA (INAKTIVIRANA):
_Leptospira interrogans,_
serotip Icterohaemorrhagiae,
serovar Icterohaemorrhagiae, soj MSLB 1089
ALR** titar ≥ 1:51
_Leptospira interrogans, _
serotip Canicola,
_ _
serovar Canicola, soj MSLB 1090
ALR** titar ≥ 1:51
_Leptospira kirschneri, _
serotip Grippotyphosa,
_ _
serovar Grippotyphosa
_,_
soj MSLB 1091
ALR** titar ≥ 1:40
_Leptospira interrogans, _
serotip Australis,
_ _
serovar Bratislava
_,_
soj MSLB 1088
ALR** titar ≥ 1:51
Virus bjesnoće, soj SAD Vnukovo-32
≥ 2,0 IU***
ADJUVANSI:
Aluminijev
hidroksid
1,8 – 2,2 mg.
*
50% infektivne doze kulture tkiva.
**
mikro aglutinacijska – litička
reakcija antitijela.
***
Internacionalne jedinice.
19
Liofilizat:
spužvasta tvar bijele boje.
Suspenzija:
ružičaste boje sa sitnim talogom.
4.
INDIKACIJE
Aktivna imunizacija pasa od 8 – 9 tjedana starosti:
−
sprječavanje kliničkih
znakova (iscjedak iz nosa i očiju) i smanjivanje izlučivanja
virusa,
uzrokovanih virusom parainfluence,
−
sprječavanje kliničkih
znakova, infekcije i izlučivanja
mokraćom, uzrokovanih s
_L. interrogans, _
serotip Australis, serovar Bratislava,

                                
                                Read the complete document
                                
                            

Summary of Product characteristics

                                1
DODATAK I
SAŽETAK OPISA SVOJSTAVA
2
1.
NAZIV VETERINARSKO-MEDICINSKOG PROIZVODA
Versican Plus Pi/L4R liofilizat i suspenzija za suspenziju za
injekciju za pse
2.
KVALITATIVNI I KVANTITATIVNI SASTAV
Svaka doza od 1 ml sadržava:
DJELATNE TVARI:
LIOFILIZAT (ŽIVI ATENUIRANI):
MINIMALNO
MAKSIMALNO
Pseći parainfluenca virus, tip 2, soj CPiV-2 Bio 15
10
3,1
TCID
50
*
10
5,1
TCID
50
SUSPENZIJA (INAKTIVIRANA):
_Leptospira interrogans,_
serotip Icterohaemorrhagiae,
serovar Icterohaemorrhagiae, soj MSLB 1089
ALR** titar ≥ 1:51
_Leptospira interrogans, _
serotip Canicola,
_ _
serovar Canicola, soj MSLB 1090
ALR** titar ≥ 1:51
_Leptospira kirschneri, _
serotip Grippotyphosa,
_ _
serovar Grippotyphosa
_,_
soj MSLB 1091
ALR** titar ≥ 1:40
_Leptospira interrogans, _
serotip Australis,
_ _
serovar Bratislava
_,_
soj MSLB 1088
ALR** titar ≥ 1:51
Virus bjesnoće, soj SAD Vnukovo-32
≥ 2,0 IU ***
*
50% infektivne doze tkivne kulture.
**
mikro aglutinacijska – litička
reakcija antitijela.
***
internacionalne jedinice.
ADJUVANSI:
Aluminijev
hidroksid
1,8 – 2,2 mg.
Potpuni popis pomoćnih tvari vidi u odjeljku
6.1.
3.
FARMACEUTSKI OBLIK
Liofilizat i suspenzija za suspenziju za injekciju.
Vizualni
izgled:
Liofilizat:
spužvasta tvorba bijele boje.
Suspenzija: ružičaste boje sa sitnim talogom.
4.
KLINIČKE POJEDINOSTI
4.1
CILJNE VRSTE ŽIVOTINJA
Psi
4.2
INDIKACIJE ZA PRIMJENU, NAVESTI CILJNE VRSTE ŽIVOTINJA
Aktivna imunizacija pasa 8 – 9 tjedana starosti:
−
sprječavanje kliničkih
znakova (iscjedak iz nosa i očiju) i smanjivanje
izlučivanja
virusa,
uzrokovanih virusom parainfluence,
3
−
sprječavanje kliničkih
znakova, infekcije i izlučivanja
mokraćom, uzrokovanih s
_L. interrogans , _
serotip Australis, serovar Bratislava,
−
sprječavanje kliničkih
znakova, izlučivanja
mokraćom, te smanjenje infekcije, uzrokovanih s
_L. interrogans,_
serotip Canicola, serovar Canicola i
_L. interrogans,_
serotip
Icterohaemorrhagiae, serovar Icterohaemorrhagiae,
−
sprječavanje kliničkih
znakova, smanjenje infek
                                
                                Read the complete document
                                
                            

Documents in other languages

Patient Information leaflet Patient Information leaflet Bulgarian 17-05-2019
Summary of Product characteristics Summary of Product characteristics Bulgarian 17-05-2019
Public Assessment Report Public Assessment Report Bulgarian 20-10-2014
Patient Information leaflet Patient Information leaflet Spanish 17-05-2019
Public Assessment Report Public Assessment Report Spanish 20-10-2014
Patient Information leaflet Patient Information leaflet Czech 17-05-2019
Public Assessment Report Public Assessment Report Czech 20-10-2014
Patient Information leaflet Patient Information leaflet Danish 17-05-2019
Public Assessment Report Public Assessment Report Danish 20-10-2014
Patient Information leaflet Patient Information leaflet German 17-05-2019
Public Assessment Report Public Assessment Report German 20-10-2014
Patient Information leaflet Patient Information leaflet Estonian 17-05-2019
Public Assessment Report Public Assessment Report Estonian 20-10-2014
Patient Information leaflet Patient Information leaflet Greek 17-05-2019
Public Assessment Report Public Assessment Report Greek 20-10-2014
Patient Information leaflet Patient Information leaflet English 17-05-2019
Public Assessment Report Public Assessment Report English 20-10-2014
Patient Information leaflet Patient Information leaflet French 17-05-2019
Public Assessment Report Public Assessment Report French 20-10-2014
Patient Information leaflet Patient Information leaflet Italian 17-05-2019
Public Assessment Report Public Assessment Report Italian 20-10-2014
Patient Information leaflet Patient Information leaflet Latvian 17-05-2019
Public Assessment Report Public Assessment Report Latvian 20-10-2014
Patient Information leaflet Patient Information leaflet Lithuanian 17-05-2019
Summary of Product characteristics Summary of Product characteristics Lithuanian 17-05-2019
Public Assessment Report Public Assessment Report Lithuanian 20-10-2014
Patient Information leaflet Patient Information leaflet Hungarian 17-05-2019
Summary of Product characteristics Summary of Product characteristics Hungarian 17-05-2019
Public Assessment Report Public Assessment Report Hungarian 20-10-2014
Patient Information leaflet Patient Information leaflet Maltese 17-05-2019
Public Assessment Report Public Assessment Report Maltese 20-10-2014
Patient Information leaflet Patient Information leaflet Dutch 17-05-2019
Public Assessment Report Public Assessment Report Dutch 20-10-2014
Patient Information leaflet Patient Information leaflet Polish 17-05-2019
Public Assessment Report Public Assessment Report Polish 20-10-2014
Patient Information leaflet Patient Information leaflet Portuguese 17-05-2019
Summary of Product characteristics Summary of Product characteristics Portuguese 17-05-2019
Public Assessment Report Public Assessment Report Portuguese 20-10-2014
Patient Information leaflet Patient Information leaflet Romanian 17-05-2019
Public Assessment Report Public Assessment Report Romanian 20-10-2014
Patient Information leaflet Patient Information leaflet Slovak 17-05-2019
Public Assessment Report Public Assessment Report Slovak 20-10-2014
Patient Information leaflet Patient Information leaflet Slovenian 17-05-2019
Summary of Product characteristics Summary of Product characteristics Slovenian 17-05-2019
Public Assessment Report Public Assessment Report Slovenian 20-10-2014
Patient Information leaflet Patient Information leaflet Finnish 17-05-2019
Public Assessment Report Public Assessment Report Finnish 20-10-2014
Patient Information leaflet Patient Information leaflet Swedish 17-05-2019
Public Assessment Report Public Assessment Report Swedish 20-10-2014
Patient Information leaflet Patient Information leaflet Norwegian 17-05-2019
Summary of Product characteristics Summary of Product characteristics Norwegian 17-05-2019
Patient Information leaflet Patient Information leaflet Icelandic 17-05-2019
Summary of Product characteristics Summary of Product characteristics Icelandic 17-05-2019